#460: FDA AI Regulations: Master the QA/RA Skills to Stay Ahead

The FDA is actively shaping the regulatory landscape for Artificial Intelligence (AI) and Machine Learning (ML) in real time. As the agency expands its internal expertise through the Digital Health Center of Excellence, FDA reviewers are becoming highly sophisticated. The era of submitting vague algorithm descriptions is over, paving the way for a more level playing field that rewards companies executing documentation correctly.

Navigating this evolving space requires a dual-front approach for global medical device companies. Manufacturers must balance the FDA's framework with the EU AI Act, which classifies AI medical devices as high-risk systems demanding rigorous conformity assessments and human oversight. Fortunately, a robust quality management system designed around proactive frameworks, such as the Predetermined Change Control Plan (PCCP), can bridge the gap between US and international expectations.

For Quality Assurance and Regulatory Affairs (QA/RA) professionals, this shift represents an unprecedented career opportunity. The future belongs to those who combine regulatory fluency with AI literacy. Success in the MedTech industry will not belong solely to the most complex algorithm, but to the companies and professionals who build compliant, disciplined systems around their AI technologies.

Key Timestamps

• 00:19 – Introduction to the current state of FDA AI regulation and leadership transitions.
• 01:34 – The role of the FDA Digital Health Center of Excellence and shifting reviewer expectations.
• 02:08 – Navigating global regulations: Balancing the EU AI Act and EU MDR.
• 02:46 – The 5 guiding principles for AI/ML-based Software as a Medical Device (SaMD).
• 03:41 – Analyzing FDA warning letters: Why documentation takes precedence over algorithm performance.
• 04:19 – Bridging the language barrier between AI engineers and FDA reviewers in submissions.
• 05:27 – The future of QA/RA careers: The rising demand for AI-literate regulatory professionals.
• 06:21 – Actionable strategies to stay ahead: Implementing PCCPs early and training quality teams.
• 07:23 – Treating post-market surveillance for AI products as an evolving product lifecycle.

Quotes

"The companies getting in trouble aren't the ones with bad AI, they're the ones with incomplete quality systems." - Etienne Nichols

"Your job in a regulatory submission is not to demonstrate that your AI is sophisticated. Your job is to demonstrate that it's safe and effective in its intended use." - Etienne Nichols

Takeaways

• Build Your PCCP First: Develop your Predetermined Change Control Plan (PCCP) concurrently with or prior to algorithm development to ensure post-clearance modifications match your design process.
• Close the Team Knowledge Gap: Educate quality engineering teams on fundamental AI concepts like training data, validation datasets, and demographic representation before facing regulatory audits.
• Proactively Audit Your DHF: Review your existing Design History File (DHF) against current FDA AI guidance documents well ahead of submission deadlines to eliminate documentation gaps without timeline pressure.
• Evolve Post-Market Surveillance: Treat your AI post-market surveillance plan as a living product by implementing version control, clear ownership, and defined thresholds to detect algorithm drift.
• Achieve Dual Literacy for Career Growth: QA/RA professionals who master both regulatory frameworks and basic AI literacy will position themselves at the top of an uncrowded talent pool.

References

• FDA, Health Canada, & UK MHRA Joint Statement (2022): The five joint gui